Background Experimental studies suggest that metabolic myocardial support by intravenous (IV) glucose, insulin, and potassium (GIK) reduces ischemia-induced arrhythmias, cardiac arrest, mortality, progression from unstable angina pectoris to acute myocardial infarction (AMI), and myocardial infarction size. However, trials of hospital administration of IV GIK to patients with ST-elevation myocardial infarction (STEMI) have generally not shown favorable effects possibly because of the GIK intervention taking place many hours after ischemic symptom onset. A trial of GIK used in the very first hours of ischemia has been needed, consistent with the timing of benefit seen in experimental studies.
Background
The IMMEDIATE Trial was a double-blind randomized controlled clinical effectiveness trial sponsored by the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) to evaluate the impact of intravenous (IV) glucose, insulin, and potassium ("GIK") for acute coronary syndromes (ACS). The Trial tested whether myocardial metabolic support by GIK, administered as early as possible to patients with ACS, would reduce progression of unstable angina pectoris (UAP) to acute myocardial infarction (AMI), cardiac arrest, mortality, heart failure (HF), and other end points related to potential myocardial salvage and the biological mechanisms related to such effects.
Prior experimental and clinical studies have shown that GIK metabolically protects the myocardium against ischemic injury and related metabolic perturbations and slows the rate of ischemic cell death. [1] [2] [3] [4] [5] [6] [7] [8] Research also suggests that for patients with electrocardiogram (ECG) ST-segment elevation myocardial infarction (STEMI), GIK may lengthen the time window for benefit from coronary reperfusion, thereby enhancing the effect of reperfusion in limiting infarction. 9 These benefits are clearly related to the time that GIK is administered in the course of cardiac ischemia, with effectiveness increasing with early administration. 10 However, although GIK has been tested for AMI in hospital settings, it had not previously been tested clinically for all ACS, that is, before manifest infarction; nor had it been tested when used as early as possible, in initial prehospital emergency medical service (EMS) care. Such an approach would avoid delays in treatment while getting to the hospital as well as further delays at the hospital. To address these issues, this trial focused on immediate GIK treatment at the earliest possible time in the treatment of ACS, in EMS settings.
Rationale for study approach and design

Target patients and treatment model
The IMMEDIATE Trial treatment model is based on the fact that in actual clinical practice, the decision to treat immediately with GIK must be made using presenting features of ACS rather than a confirmed AMI diagnosis; ischemic myocardium will be most salvageable early in the ischemic process, before progressing to infarction, usually within 6 hours. An agent that protects ischemic myocardium from progressing to necrosis could prevent or mitigate infarction in those early hours and, thereby, preserve left ventricular (LV) function.
The importance of very early treatment is also underscored by the fact that 50% of deaths from ACS/ AMI occur in the first hour, frequently attributed to ischemia-related ventricular fibrillation (VF) progressing to cardiac arrest. Ischemia-related arrhythmias and cardiac arrest are considered related to increasing levels of cellular free fatty acids (FFAs) and their derivatives that accumulate during ischemia. Arrhythmias and cardiac arrest are thought to be due to FFA detergentlike properties associated with increased sarcolemmal and mitochondrial membrane damage, increased intracellular calcium, primary arrhythmias, and accelerated functional deterioration. 1, 11 Because GIK decreases both circulating FFA levels and myocardial FFA uptake, it could reduce susceptibility to ischemic VF and cardiac arrest, with impact being dependent on how early in ischemia it is instituted.
In prior trials of GIK, the interval from symptom onset to GIK initiation was the total time the patient waited before calling for medical attention, the time elapsed before the ambulance arrived (or the patient arrived at a hospital), the time taken to diagnose ACS, and the time required to start IV GIK. In addition, prior trials waited until myocardial infarction (MI) was evident and, in recent trials, the time until starting GIK had varied from 2 8 to 11 hours 6 ; in earlier trials, it was up to several days ( Figure 1) . 12, 13 Given that cardiac arrest and death most commonly occur in the first hour and that the optimal opportunity for myocardial salvage also occurs early, these trials were not optimally designed to test GIK's impact on these outcomes.
In addition, if GIK administration is to prolong the timedependent potential benefit from coronary reperfusion for STEMI, then it must be started as soon as possible. Such a GIK effect will be related to the time spent in transport to a cardiac center where reperfusion therapy can be performed and the promptness of treatment, once there, which, in some circumstances, could be a considerable period. This emphasized the need to test GIK in the range of "real-world" settings with the broad inclusion characteristic of effectiveness trials.
Clinically, to accrue these time-dependent benefits, target patients must be those with suspected and high likelihood ACS, not those with already established AMI. When a physician or paramedic first encounters a patient with ACS, often it is not possible to distinguish UAP from AMI, and to wait for the diagnosis of AMI to become clear would be to miss the most important period for benefit from GIK. Moreover, GIK is likely to be beneficial throughout the evolution of ACS, not just upon establishment of AMI. Indeed, early GIK treatment of ACS may abort the evolution of UAP to AMI. Rogers et al 14 found that among patients with ischemic chest pain randomized to GIK or control, AMI was confirmed in 64% (61/95) of those treated with GIK vs 77% (73/95) of controls, a 17% relative reduction in progression to AMI (P = .06).
Thus, for general clinical use, administering GIK very early requires very rapid and accurate identification of ACS in EMS and emergency department (ED) settings. To do this, in the IMMEDIATE Trial, an approach was developed for paramedic decision support by the electrocardiograph-based acute cardiac ischemia timeinsensitive predictive instrument (ACI-TIPI) and thrombolytic predictive instrument (TPI). [15] [16] [17] The ACI-TIPI calculates a 0 to 100% prediction of ACS for a given individual and has been shown to aid clinicians' assessment and triage of patients presenting with chest pain and other symptoms suggestive of acute ischemia. 16, 17 The TPI has been shown to improve recognition and treatment of STEMI, especially for patients who are less likely to be recognized for use of reperfusion therapy, such as women and those with nonanterior STEMI, and when consultation with off-site physicians is required, such as in very small EDs or EMS. 15, 17 The ACI-TIPI and TPI are available in conventional electrocardiographs' software so that their predictions are printed on the patient's ECG to supplement clinicians' decision making. In the wide variety of IMMEDIATE Trial sites, we showed that the use of these predictive instruments, based on an ACI-TIPI threshold of ≥75% probability of ACS and/or detection of a STEMI by the TPI, improved recognition of ACS and STEMI to the level needed for the Trial. 17 
GIK formula
Based on dose-response studies of glucose and insulin aimed to maximize myocardial glucose uptake and decrease arterial FFA levels and myocardial FFA uptake, and data showing improved cardiac function, decreased ventricular arrhythmias, and a trend toward a decreased mortality risk, the IMMEDIATE Trial used the GIK formula of Rackley et al 4 : 30% glucose (300 g/L), 50 units of regular insulin per liter, and 80 mEq of KCl/L, given IV at 1.5 mL per kg per hour, approximately 100 mL/h for a 70-kg patient.
In studies of the formula of Rackley et al 4 , during GIK treatment of AMI, despite the significant volume infusion, pulmonary capillary pressure decreased and cardiac output and ejection fraction increased. This presumably resulted from improved systolic and/or diastolic function, consistent with experiments showing that glucose and insulin treatment can improve both systolic and diastolic dysfunctions during ischemia and reperfusion. Nonetheless, for the IMMEDIATE Trial, concern about the volume load during AMI, especially in the setting of HF, led to 2 modifications in the use of the regimen of Rackley et al. First was exclusion of the approximately 5% of patients with ACS (10% of AMI) manifesting significant pulmonary congestion and/or cardiogenic shock (Killip classes 3 and 4). These patients have the highest mortality risk and, thus, might have the greatest potential to benefit from GIK, but they also may be at significant risk for worsening of their pulmonary Time from symptom onset to the use of GIK in major trials.
congestion by GIK infusion, which would be challenging to manage in the EMS setting. Moreover, patients with HF receiving placebo would receive an infused volume without the potential benefit of GIK, an unjustifiable risk. Second was the use of 12 hours rather than the 48 hours of infusion that Rackley and others had used. This, too, was related to concerns about the volume load leading to HF, especially for placebo arm participants who would receive no potential benefit, and to make the logistics as unobtrusive as possible and consistent with the emphasis on testing very early use of GIK. Also, although prior trials had demonstrated the safety of GIK infusion, given that adverse effects are related to duration of administration, their occurrence could be mitigated by shorter administration.
Methods
Study hypotheses
Based on the factors outlined previously, the original primary study hypothesis was that GIK would reduce all-cause mortality; the 2 primary study end points were survival at 30 days and at 1 year. Major secondary hypotheses were that GIK would reduce the prehospital and in-hospital incidence of cardiac arrest or mortality, that it would reduce the development of HF, and that it would reduce progression of UAP to AMI. The study design then included both EMS and ED patients. However, at initiation, based on the recommendation of the NHLBI Protocol Review Committee, with which the investigators agreed, the decision was made to enroll only EMS patients, to fully focus on the immediate use of GIK as early as possible in prehospital settings. However, eliminating patients who would have been enrolled in EDs reduced study candidates by more than 50%. Because enrollment in the prehospital setting was difficult and required much more resources than were available to the Trial, enrollment of the 15,450 participants needed to provide acceptably high statistical power to detect the likely impact on the mortality end points was no longer realistic. To adapt to this, in conjunction with the NHLBI and its IMMEDIATE Trial Data Safety and Monitoring Board (DSMB), the Trial was temporarily suspended and the study hypotheses reordered to adapt to the projected 880 participants that were eventually enrolled with the new EMS-based approach. The new primary end point became progression to completed infarction, for which there would be sufficient statistical power, and accordingly, the original primary mortality hypothesis joined the other major secondary hypotheses. The revised list of hypotheses, testing GIK vs placebo, was as follows:
Primary hypothesis. Immediate GIK will reduce progression of UAP to AMI, as evidenced by fewer patients having biomarker and ECG evidence of AMI.
Major secondary hypotheses
• Immediate GIK treatment will lead to better survival at (a) 30 days and (b) 1 year.
• Immediate GIK will reduce the prehospital/in-hospital incidence of cardiac arrest, VF, or ventricular tachycardia requiring defibrillation or cardioversion, or mortality.
• Immediate GIK treatment will reduce patients' propensity for developing HF, reflected by lower rates of (a) hospitalization for HF or mortality within 30 days and (b) hospitalization for HF or mortality within 1 year.
Other secondary hypotheses
• The impact of GIK on mortality, cardiac arrest, and development of HF will be modified by time duration from ischemic symptom onset until the initiation of GIK.
• For patients with ACS presenting with ECG ST-segment elevation, immediate GIK will reduce the composite end point of prehospital or in-hospital cardiac arrest, hospitalization for HF, or mortality.
• For patients receiving coronary reperfusion treatment of STEMI, immediate GIK treatment will modify (a) the overall impact of reperfusion therapy on the composite end point of prehospital/in-hospital cardiac arrest, hospitalization for HF, or mortality and (b) the influence of time duration from initial presentation (EMS or ED) until reperfusion.
• In a sample of patients with ACS to study biological mechanisms, immediate GIK use will reduce FFA levels and increase the proportion of FFA comprised by n-3 polyunsaturated fatty acids.
• In the biological mechanism sample, immediate GIK use will be associated with physiologic indicators reflecting a lower propensity for HF at 30 days including (a) smaller infarct size by sestamibi perfusion imaging, (b) better preserved LV function by gated single-photon emission computed tomography (SPECT) imaging, and (c) lower brain natriuretic peptide (BNP) levels.
Enrollment and intervention
During the enrollment period, at participating EMS systems, all patients for whom a 12-lead ECG was obtained for the evaluation of chest pain or other symptoms suggestive of ACS in the prehospital setting had a screening checklist completed by their paramedic, to determine eligibility for enrollment. To be candidates for the IMMEDIATE Trial (ClinicalTrials.gov identifier: NCT00091507), patients needed to be 30 years or older and to be having ACS as determined by the EMS paramedic, based on symptoms and presenting EMS 12-lead ECG. Paramedic identification of potential study participants was aided by electrocardiograph-based ACI-TIPI and TPI decision support, as detailed elsewhere, 17 and for most of the Trial, this included the use of a ACI-TIPI threshold of 75% or greater predicted probability of having ACS and/or the detection of STEMI by the TPI. 17 (EMS defibrillator-electrocardiographs were provided with ACI-TIPI and TPI capabilities by their manufacturers, PhysioControl [Redmond, WA], Philips Healthcare [Andover, MA], and Zoll Medical [Chelmsford, MA].) Patients were excluded if they had end-stage renal failure requiring dialysis, were hemodynamically unstable (systolic blood pressure b100 mm Hg), were determined to be unable to give consent due to impaired reasoning, altered mental status or dementia, or had clinically significant HF (more than basilar rales or Killip class 3 or 4 AMI).
To obtain informed consent, we followed the Exception from Informed Consent Requirements for Emergency Research per the Code of Federal Regulations 21 CFR 50.24, 18 including community consultation, institutional review board approval, and full-written consent once stabilized in the hospital. 19 For the ancillary biological mechanism study, additional written consent was obtained for blood tests during the first 12 hours and to have 30-day assessment by LV imaging scan and a blood test for BNP level.
Randomization
The IMMEDIATE Data Coordinating Center (DCC) generated and provided a randomization table to the manufacturer of the study drug; the randomization block size was 4. Intervention and placebo drug infusion packets, labeled and shipped from the manufacturer to the study centers for distribution to the paramedic units, were identical in appearance and contained no treatment-identifying information. The treatment could only be unblinded by comparing the patient identifier, preprinted on the packet, to the randomization schedule, which was held confidentially and locked and stored at the DCC, and not available to any participants or personnel involved in the conduct of the study. Thus, double-blinded randomization occurred when the IV study drug was started. This approach, based on the blinded study drug packet used, was controlled and not subject to investigator inclusion bias and, importantly, avoiding delaying EMS care or interfering with paramedics' work.
Clinical and laboratory evaluation
During the 12-hour study drug infusion, glucose and potassium levels were tested at 3 times: (1) upon ED arrival, (2) at 6 hours after the start of the study drug infusion, and (3) once the infusion was completed or stopped prematurely. Treatment of abnormal test results or changes in fluid status was according to standard practice.
Participants in the biological mechanism cohort, a subset of enrolled patients, had FFA levels and fractionation drawn shortly after hospital arrival, at 6 hours, and at 12 hours. Those who proved to have ACS returned at 30 days for sestamibi LV imaging and a BNP blood test.
Core Laboratories included the LV Core Laboratory at Tufts Medical Center that interpreted imaging studies; OmegaQuant in Sioux Falls, SD, that analyzed the FFA samples; and the core laboratory of Tufts Clinical and Translational Science Institute that ran the BNP, insulin levels, and other analytes.
Assignment of diagnosis
To allow for real-time monitoring during enrollment, based on prehospital, ED, and 24-hour ECGs, biomarker test results, information on ED presentation and hospitalization, results of cardiac catheterization, and other tests, site investigators assigned diagnoses from 4 main categories-AMI by Killip Class, UAP by Canadian Class, non-ACS cardiac disease, and noncardiac disease-based on the systems used in our prior ACS trials. 15, 16, 20 For study end points, independently, the Clinical Events Committee was provided the same documents and conducted a formal adjudication process to determine the confirmed diagnosis of AMI, and made the additional determination as to whether a participant had an aborted MI. In assigning diagnoses, reviewers were blinded to the study group, glucose and potassium tests, and to whether the study drug was stopped early.
Study participant follow-up
At 30 days and 1 year after study entry, all-cause mortality and hospitalization for HF since the study admission are assessed. One-year follow-up will be completed in summer of 2012. For all rehospitalizations during the follow-up period, source documents are provided for review by the Clinical Events Committee, to determine if the hospitalization was related to HF.
Study organization, administration, and funding
The IMMEDIATE Trial Coordinating Center was located in the Center for Cardiovascular Health Services Research at Tufts Medical Center, Boston, MA, as was the DCC, with participation of Harvard Clinical Research Institute, Boston, MA, where an independent statistician who generated periodic interim safety reports to the DSMB was located. The DSMB was appointed by NHLBI and provided oversight during enrollment to ensure safe and ethical study conduct. The Scientific Advisory Committee was made up of leaders in emergency medicine, cardiology, and cardiac physiology, with particular research and clinical expertise in treatment of ACS and the use of GIK.
The 13 study sites ranged widely by location, city size, type of EMS system, and sociodemographic features, as shown in Table I . 
Primary trial analysis
The flow of enrollment and the analytic groups are shown in the enrollment plan, in Figure 2 . Of the hypotheses listed above, the last 2 were assessed on the subset of patients shown as the "biological mechanism cohort."
Sample size
Power analysis indicated that at a 2-sided .05 level of significance, an evaluable sample of 800 subjects (400 in each of GIK and placebo) would provide 90% power to detect a relative 20.4% reduction in the primary end point rate of adjudicated AMI for GIK vs placebo from 55.7% to 44.3% (or a difference of 11.4%). At least 880 subjects would need to be randomized to account for an anticipated attrition and patients withdrawing consent; the trial ultimately randomized 911 and enrolled 871 participants. One hundred forty-three participants with ACS were enrolled into the biological mechanism cohort.
Statistical methodology
The primary analyses were on an intent-to-treat (ITT) cohort including all randomized participants who provided informed consent; patients were analyzed according to treatment received. Analyses also were conducted on a modified-intent-totreat (MITT) cohort, constituting all those in the ITT cohort who were considered by the physician at the receiving ED to be having ACS and, therefore, were continued on the study drug. The MITT cohort most closely matches the way that GIK would be used in practice: initiated in the EMS setting and continued in the ED only for patients whom the ED physician considered to be having ACS. An additional analytic "efficacy" cohort was those who were confirmed to be having ACS (AMI or UAP) in the initial 24 hours as determined by site investigator review and who received their full randomized treatment course or who died during treatment infusion. A subsample of MITT patients who received treatment for at least 8 hours were eligible for enrollment into the biological mechanism cohort; patients enrolled in this cohort received additional testing to provide FFA, BNP, and SPECT scan information needed to address the biological mechanism hypotheses.
Treatment comparisons on the primary end point were carried out using logistic regression adjusting for the 13 study sites at a 2-sided .05 level of significance. Assessment of treatment-by-center interaction on the primary end point was carried out at the .10 level of significance. These analyses were carried out on the ITT (primary), MITT, and efficacy analysis cohorts. Because of the potential loss of randomization in the MITT and evaluable analysis sets, treatment comparisons were also adjusted for quintiles of a propensity score for treatment allocation. For adjusted analyses, forced logistic regression models were used for propensity scores that predicted treatment group (GIK/placebo) that included participants' age, sex, ACI-TIPI score, systolic blood pressure, chief complaint, current home medications, and medical history of MI, coronary bypass surgery, HF, coronary angioplasty, diabetes, hypertension, and stroke as independent variables.
For the biological mechanism cohort, mean FFA levels were compared across time periods using a generalized estimating equation (GEE) analysis of variance, for which the total FFA level was the dependent variable and treatment (GIK vs control) and time from the start of randomized drug infusion were the independent variables. The GEE model also included a subject factor to adjust for the design where each subject had multiple measurements (ie, the GEE approach, which accounted for the within-subject correlation). Also, on the biological mechanism cohort, 30-day mean infarct size, LV ejection fraction, and BNP were compared between the GIK and control study groups, using analysis of variance or rank analysis of variance, depending on the distribution, adjusting for study center.
Other secondary hypotheses involving binary or continuous outcomes were analyzed in a similar way to the above. Hypotheses involving time-to-event outcomes were assessed using Cox proportional hazard regression adjusting for propensity quartile. All secondary hypotheses were carried out on a 2-sided .05 level of significance.
Summary
The IMMEDIATE Trial was a placebo-controlled, double-blinded, randomized NIH-supported trial of the use of GIK for ACS, that is, threatened or established AMI. It was an "effectiveness trial" rather than an "efficacy trial," and thus, inclusion and treatment were done as it would be in widespread usual practice. The IV GIK was administered by paramedics in the field using the 12-lead electrocardiographs with decision support by the ACI-TIPI and TPI that automatically print on ECGs a patient's probability of ACS and/or the presence of STEMI. 17 The inclusion criteria were broad: patients 30 years or older calling 9-1-1 with a clinical picture suggesting ACS/AMI based on paramedic judgment, with a prehospital ECG with at least one of the following: (1) ACI-TIPI probability of ACS of 75% or more, (2) detection by TPI of STEMI, (or 3) definitive STEMI deemed by local standards for which the receiving hospital catheterization laboratory would be notified based on local-community EMS procedures.
The primary end point was progression to AMI confirmed by biomarkers and ECG; major secondary end points included 30-day mortality, 1-year mortality, the composite of in-hospital mortality or cardiac arrest, the composite of 30-day mortality or hospitalization for HF, and the composite of in-hospital cardiac arrest, 30-day mortality, or hospitalization for HF. Biological mechanism cohort end points included infarct size by sestamibi perfusion imaging at 30 days, LV ejection fraction by sestamibi SPECT scanning at 30 days, BNP at 30 days, and metabolic parameters. If impact is seen on these end points, we believe that emergency cardiac practice will be altered-and because it appears to work in a broad array of usual-care settings, the IMMEDIATE Trial approach could be adopted widely. However, even before the pending results for these end points, the Trial has already demonstrated a model of very early prehospital paramedic recognition and treatment of patients with ACS/AMI/STEMI, which provides an opportunity for other important EMS-based interventions in the first hours. 17 In sum, the IMMEDIATE Trial tested GIK myocardial metabolic support in a way analogous to how it has worked in experimental research, in patients with ACS, that is, with threatening or established AMI, at the time they are most at risk, in the very first hours, which is most often in the EMS setting. We consider this an example of translation of experimental laboratory findings into clinical care and, in this case, into wide use in the community, an important goal of NIHsupported research.
